Clinical Trials Browser

gedatolisib × Breast × 90 days × Clear all

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis